Supplementary Table S1. ALFA-0701 - Adverse Events in Induction from FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia

Emily Y. Jen,Chia-Wen Ko,Jee Eun Lee, Pedro L. Del Valle, Antonina Aydanian, Charles Jewell,Kelly J. Norsworthy,Donna Przepiorka,Lei Nie,Jiang Liu, Christopher M. Sheth,Marjorie Shapiro,Ann T. Farrell,Richard Pazdur

crossref（2023）

引用 0|浏览1

暂无评分

摘要

Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要